Global Expansion Potential Rapid Medical has demonstrated regulatory traction and market validation through 2026 DISTALS trial results presented at ESOC and Chinese approval for the TIGERTRIEVER device, signaling readiness to expand into US, Europe, and APAC markets via distributors and regional partnerships.

Clinical Validation Full DISTALS trial results provide robust clinical evidence supporting the safety and effectiveness of their adjustable, brain visible neurovascular devices, enabling value based conversations with stroke centers and procurement teams.

Strategic Partnerships Past investments and partnerships, notably MicroPort's $20M investment in 2019 and the appointment of a President for Americas in 2021, suggest a proven route for co development and regional distribution to accelerate US, Canada, and LATAM growth.

Product Portfolio Fit The TIGERTRIEVER revascularization device and COMANECI embolization assist device address ruptured wide neck intracranial aneurysms and revascularization needs, offering surgeons devices that are fully visible and adjustable in the brain, a compelling differentiator for neurovascular centers.

Commercial Readiness With a focused team size and increasing visibility through ESOC participation, plus a strategic product portfolio, Rapid Medical is positioned to target mid to large stroke centers and neurovascular specialists seeking innovative technologies and evidence backed outcomes.